Clinical and biological characteristics of the cohort upon ¹⁸FDG PET/CT use.

<p>Clinical and biological characteristics of the cohort upon ¹⁸FDG PET/CT use.</p

Diagnostic algorithm to manage patients with autosomal dominant polycystic kidney disease (ADPKD) presenting with suspected acute cyst complication.

<p>*, On the basis of the conventional management (including blood and urine analyses and abdomen imaging) of any patient with febrile abdominal pain in emergency conditions (33).</p

Selection process of patients with autosomal dominant polycystic kidney disease (ADPKD) presenting with suspected acute cyst complication.

<p>One given patient may present with different types of cyst complications</p

Clinical and biological characteristics of the cohort.

<p>Clinical and biological characteristics of the cohort.</p

Distribution of ¹⁸FDG-PET/CT imaging in patients with autosomal dominant polycystic kidney disease (ADPKD) presenting with suspected cyst complication.

<p>The final diagnosis is provided on the basis of the entire work-up.</p

PET/CT imaging of DENA-induced rats injected intra-arterially with ⁶⁸Ga-SBMP and macroscopic view of the liver.

<p>On the macroscopic view, (open abdominal view) the major tumors nodules are identified by white <i>arrowhead</i>s for the rat n°3 and for the rat n°8 the <i>dashed line</i> delimits the upper tumorous part of the liver. In the column displaying the ROI on the corresponding PET/CT slice: the <i>orange ROI</i> corresponds to the liver, the <i>green</i> one to the intraperitoneal area and the <i>pink</i> one to the activity counted as the rest of the body. <i>Abbreviations</i>: <i>CT (Computed Tomography); PET (Positron Emission Tomography); MIP (Maximum Intensity Projection) and ROI (Region of Interest)</i>.</p

Influence on the RCP of several parameters during the ¹⁸⁸Re radiolabeling of SBMP.

<p>(<b>a</b>) RCP of 300mg SBMP radiolabeled kits with varied amount of SnCl₂. (<b>b</b>) RCP of 1mg SnCl₂ radiolabeled kits with varied amount of SBMP. (<b>c</b>) RCP of 300mg SBMP, 1mg SnCl₂ kits with varied amount of activity. (<b>d</b>) RCP of 300mg SBMP, 1mg SnCl₂ kits with varied amount of gluconate.</p

⁶⁸Ga radiolabeling of SBMP.

<p>(<b>a</b>) Direct radiolabeling of varied amount of SBMP or native starch with ⁶⁸GaCl₃ eluate. (<b>b</b>) Optimization of ⁶⁸Ga radiolabeling of varied amount of SBMP with addition of 0.5mL of sodium acetate trihydrate 1M (pH4.1).</p

<i>In vitro</i> stability studies: ⁶⁸Ga radiolabeling of 100mg SBMP kit with 55μg of SnCl₂.

<p><i>In vitro</i> stability studies: ⁶⁸Ga radiolabeling of 100mg SBMP kit with 55μg of SnCl₂.</p